This segment focuses on the research and development of therapies targeting the CD47 protein, a key immune checkpoint in cancer. Trillium's lead programs, TTI-621 and TTI-622, are SIRPaFc fusion proteins designed to block the CD47 'don't eat me' signal, allowing the immune system to recognize and eliminate cancer cells. Research and development activities include preclinical studies, Phase 1 clinical trials for various hematologic malignancies and solid tumors, and exploring combination therapies. The technologies employed involve protein engineering and antibody-drug conjugates. The therapeutic areas covered include acute myeloid leukemia, multiple myeloma, and other cancers. The patient impact is significant, as these therapies aim to improve outcomes for patients with relapsed or refractory cancers. Market positioning is based on the potential of CD47 blockade as a novel cancer treatment strategy. Future opportunities include expanding clinical trials and exploring partnerships. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to clinical trial protocols. Partnerships and collaborations are essential for advancing clinical development and commercialization.

This segment is dedicated to the development of small molecule stimulators of interferon genes (STING) agonists. These molecules are designed to activate the innate immune system by sensing cytosolic DNA, thereby promoting anti-tumor immunity. Research and development activities include the discovery phase, preclinical studies, and potentially future clinical trials. The technologies used involve small molecule drug design and development, as well as assays to assess immune activation. The therapeutic area is focused on promoting tumor immunity across various cancer types. The patient impact lies in the potential to enhance the body's ability to fight cancer. Market positioning is based on the potential of STING agonists to be used in combination with other cancer therapies. Future opportunities include advancing the program through clinical trials and exploring partnerships. Regulatory and clinical aspects involve navigating the regulatory pathway for novel drug candidates. Partnerships and collaborations are crucial for advancing the program through clinical development and commercialization.